Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 114 of 151

  1. S095018

    Regeneron UK Limited

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  2. S095031-210

    The George Institute

    Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation

    phase 2 small molecule active

    1 trial

  3. S095032-211

    The George Institute

    IDH1-mutant Glioma, IDH2-mutant Glioma

    phase 2 small molecule active

    1 trial

  4. S095035

    Tango Therapeutics

    MTAP-deleted Solid Tumors

    phase 2 small molecule active

    1 trial

  5. S1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  6. S1RA plus NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial

  7. S2023-056-01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  8. S2023-413-01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  9. S227928

    The George Institute

    "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)"

    phase 2 small molecule active

    1 trial

  10. S230815 Solution for injection 10mg/ml

    The George Institute

    KCNT1-related Developmental and Epileptic Encephalopathy

    phase 2 small molecule active

    1 trial

  11. SA-ER 500 mg

    Ultragenyx UK Limited

    GNE Myopathy

    phase 2 small molecule completed

    1 trial

  12. SA55 Injection

    Sinovac Research and Development Co.,

    Infection of Upper Respiratory Tract Caused by 2019-nCoV

    phase 2 small molecule active

    1 trial

  13. SAB-142, SODIUM CHLORIDE

    SAB Biotherapeutics

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  14. SAB-176

    SAB Biotherapeutics

    Influenza A H1N1

    phase 2 mab completed

    1 trial

  15. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 2 small molecule completed

    1 trial

  16. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Severe Postpartum Depression

    phase 2 small molecule completed

    1 trial

  17. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  18. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  19. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Huntington Disease

    phase 2 small molecule completed

    2 trials

  20. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Mild Cognitive Impairment

    phase 2 small molecule completed

    1 trial

  21. SAGE-718-matching placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  22. SAKK 01/18

    Ningbo Cancer Hospital

    Stage IIA/B seminoma

    phase 2 small molecule active

    1 trial

  23. SAKK 08/23

    Ningbo Cancer Hospital

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  24. SAKK 16/18

    Ningbo Cancer Hospital

    Resectable, locally advanced non-small cell lung cancer (NSCLC, N2)

    phase 2 small molecule active

    1 trial

  25. SAKK 38/19

    Ningbo Cancer Hospital

    Disseminated large B-cell lymphoma

    phase 2 small molecule active

    1 trial

  26. SAR421869

    Sanofi-aventis Healthcare Pty Ltd

    Usher's syndrome

    phase 2 small molecule active

    1 trial

  27. SAR422459

    Sanofi-aventis Healthcare Pty Ltd

    Congenital, hereditary and neonatal diseases

    phase 2 small molecule active

    1 trial

  28. SAR440340

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  29. SAR440340

    Sanofi Pasteur

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  30. SAR440340

    Regeneron UK Limited

    Asthma

    phase 2 small molecule completed

    1 trial

  31. SAR441566

    Sanofi Pasteur

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  32. SAR442970

    Sanofi Pasteur

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  33. SAR442970, NANOBODY® Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  34. SAR443122

    Sanofi Pasteur

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  35. SAR443765 / LUNSEKIMIG

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 2 small molecule active

    1 trial

  36. SAR443765 / LUNSEKIMIG, Matched Placebo to Test

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 2 small molecule active

    1 trial

  37. SAR444656 (KT-474)

    Kymera Therapeutics

    Atopic Dermatitis

    phase 2 small molecule terminated

    1 trial

  38. SAR444656 (KT-474)

    Kymera Therapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule terminated

    1 trial

  39. SAR444656, Matched Placebo

    Sanofi-aventis Healthcare Pty Ltd

    hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  40. SAR444881

    Regeneron UK Limited

    Solid Tumors

    phase 2 small molecule active

    1 trial

  41. SAR445761 - belumosudil, belumosudil

    Sanofi-aventis Healthcare Pty Ltd

    Chronic graft versus host disease.

    phase 2 small molecule active

    1 trial

  42. SAR447537

    Sanofi Pasteur

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule active

    1 trial

  43. SARCLISA 20mg/mL concentrate for solution for infusion.

    Pari Pharma GmbH

    Pure cell red aplasia by major ABO mismatch after allogeneic hematopoietic stem cell transplantation

    phase 2 small molecule active

    1 trial

  44. SARS-CoV-2 convalescent plasma

    United Therapeutics Europe Ltd

    SARS-CoV 2

    phase 2 mab completed

    1 trial

  45. SARS-CoV-2 mRNA Vaccine ARCT-021

    Arcturus Therapeutics Holdings

    Hematopoietic and Lymphatic System Neoplasm

    phase 2 mab active

    1 trial

  46. SAVANNAH

    AstraZeneca AB

    EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer.

    phase 2 small molecule active

    1 trial

  47. SAVANNAH/D5084C0007

    AstraZeneca AB

    EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  48. SB-318

    SANGAMO THERAPEUTICS, INC

    MPS I

    phase 2 mab terminated

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.